Jefferies Initiates Coverage On Tourmaline Bio with Buy Rating, Announces Price Target of $41
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Roger Song has initiated coverage on Tourmaline Bio (NASDAQ:TRML) with a Buy rating and set a price target of $41.

December 15, 2023 | 11:41 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jefferies has initiated coverage on Tourmaline Bio with a Buy rating and a price target of $41, indicating a positive outlook for the stock.
The initiation of coverage by a major analyst firm like Jefferies with a Buy rating typically generates positive investor sentiment and can lead to an increase in stock price in the short term. The price target of $41 suggests a significant upside potential from the current trading price, assuming the stock is trading below this target.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100